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Abstract
Understanding the molecular basis of cancer requires characterization of its genetic defects. DNA microarray technologies
can provide detailed raw data about chromosomal aberrations in tumor samples. Computational analysis is needed (1) to
deduce from raw array data actual amplification or deletion events for chromosomal fragments and (2) to distinguish causal
chromosomal alterations from functionally neutral ones. We present a comprehensive computational approach, RAE,
designed to robustly map chromosomal alterations in tumor samples and assess their functional importance in cancer. To
demonstrate the methodology, we experimentally profile copy number changes in a clinically aggressive subtype of soft-
tissue sarcoma, pleomorphic liposarcoma, and computationally derive a portrait of candidate oncogenic alterations and
their target genes. Many affected genes are known to be involved in sarcomagenesis; others are novel, including mediators
of adipocyte differentiation, and may include valuable therapeutic targets. Taken together, we present a statistically robust
methodology applicable to high-resolution genomic data to assess the extent and function of copy-number alterations in
cancer.
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Introduction
Human cancer is caused in part by irreversible structural
mutations. These can produce changes in DNA copy number at
distinct locations in the genome [1]. Aberrations of this type affect
the function of genes and thereby produce a transformed
phenotype. Comprehensive characterization of these aberrations
is a necessary step in understanding disease etiology and advancing
the development of targeted therapies [2,3,4,5,6,7]. Techniques
based on microarray technologies can simultaneously measure
thousands to millions of loci in the genome for DNA copy number
changes. They include array comparative genomic hybridization
(array CGH) and single-nucleotide polymorphism (SNP) arrays
(reviewed in [8]). These increasingly sensitive technologies have
been used to characterize not only aberrations in cancer, but also
to describe copy-number variation in the human population [9],
and the basis of genetic disorders (reviewed in [10]).
Given its capacity to identify novel oncogenes and tumor
suppressor genes in cancer, two strategies have been used to
analyze copy number array data from tumors. The traditional
approach segments noisy probe-level data in individual tumors
(dividing the genome into regions of equal copy number) [11,12],
detects aberrations with a global threshold, and heuristically
defines boundaries of regions of frequent change [13,14]. Newer
algorithmic strategies use statistical models for the analysis of
multiple samples [15,16,17]. More recently, Beroukhim et al.
proposed an interesting comprehensive framework for assessing
copy-number alteration in tumor cohorts [18]. In parallel to these
computational developments, efforts are underway to analyze
large tumor collections in a variety of cancer types, such as the
pilot phase of The Cancer Genome Atlas [19] [The Cancer
Genome Atlas (TCGA) Research Network 2008, submitted].
These will be collected using diverse sources and criteria that likely
result in intra-tumor heterogeneity and between-tumor variability.
Therefore, important unresolved issues remain. How should
alterations in individual tumors be detected and combined when
a collection of samples vary substantially in their noise character-
istics? How should the genome be divided and assessed to more
naturally reflect how alterations arise? What are the features of a
realistic background model that allow for the identification of
statistically significantly recurrent and therefore more likely
functional alterations?
In this article, we describe a computational framework that
addresses each facet of this problem. We (i) develop distinct scoring
models for different alteration types, with parameters adapted to
the characteristics of individual tumors, (ii) use segmentation
breakpoints to divide the genome for analysis that stresses the
physical nature of copy-number alteration, (iii) build a random
aberration model that approximates the biological process by
which alterations arise, and use it to (iv) assess the statistical
significance of observed alterations. This identifies genomic
regions of interest (ROI) altered more frequently than would be
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tumorigenesis (Figure 1). We apply our method to a large
repository of solid tumors to test its performance. We also apply
RAE to a novel high-resolution copy number data set generated in
our laboratories for a set of pleomorphic liposarcoma samples to
illustrate its capacity to lead to novel discoveries.
Results
Extrinsic sources of variation
In the first phase of RAE, we address the issue of reliably
detecting copy-number alteration in individual tumors. Every
tumor, including those from patients with the same type of cancer,
varies in their noise characteristics. We focus here on experimental
noise and the problem of inhomogeneity of tumor DNA. An
additional source of biological noise is structural variation, which
we address later. Regarding the former, we found at least four
distinct causes that can obscure copy-number changes in a tumor
and this motivates our departure from global thresholds for
detecting alterations. They include (i) low-quality matched non-
tumor DNA samples, (ii) stromal admixture, (iii) tumor heteroge-
neity, and (iv) incoherent tumor profile, and we discuss each in
turn.
Variation in quality of matched normal samples. Many
groups, including our own, have observed significant non-diploid
copy number in some normal samples (Figure S1). Causes may
include the source tissue (in the case of normal tissue adjacent to
tumor), differing handling protocols between tumor and normal
samples, prior chemotherapy on DNA of normal blood cells,
circulating tumor cells, and other contamination of normal DNA.
In a paired analysis, this non-neutral signal will attenuate or
otherwise alter the tumor’s signal. To prevent this, we substitute a
reference normal dataset of known diploid phenotype and analyze
tumors in an unpaired format (Methods). This reference is
generated by randomly selecting a subset of unrelated
individuals of the HapMap collection, and produces a consistent
diploid signal for tumor quantification and normalization
(Methods S1, Table S1, and Figure S2). We further reduce noise
in this new intensity ratio by segmenting individual tumors
[11,12]. This process correlates neighboring markers of common
copy number, assigning the arithmetic mean of probe-level signal
across the markers in each segment (Methods). While we avoid the
use of matched normal DNA at this step, we do use a high-quality
subset for germline event filtering after statistical assessment
(Methods).
Stromal admixture. The second source of noise is tumor
impurity, a well-documented problem [20,21]. Individual tumors
have different levels of non-tumor cell contamination. This
reduces the ratio of signal-to-noise within and between tumors.
It also compromises accurate genotyping for concurrent loss-of-
heterozygosity (LOH) analyses. This jeopardizes the detection of
two important classes of alteration: copy-neutral and deletion-
associated LOH. Contamination of tumor DNA by non-neoplastic
cell DNA exerts its effect globally, equally suppressing signal at all
loci in a tumor. Our solution is two-fold. First, we take an
individual-tumor approach to setting thresholds in log2 signal to
detect aberrations, thereby extracting information from tumors
that otherwise provide insufficient signal to detect non-diploid
copy number changes in comparison to purer tumor samples.
Second, we standardize the magnitude of alteration in all tumors
to facilitate between tumor-comparability, an important feature
when comparing tumors of varying stromal admixture.
Tumor heterogeneity. The third source of noise is perhaps
the most confounding. We see evidence of an intermediate copy
number in multiple tumor types. For example, when the value of a
monosomy (or ChrX in a male patient) establishes with confidence
the continuous log2 value corresponding to discrete integer copy
loss, this signal is often an arm-length loss that falls halfway
between diploid and the log2 value of single-copy loss. This may be
allele-specific copy number exclusive to either the maternal or
paternal chromosome, or more likely indicates the possibility that
multiple distinct but related subclones exist within a single clonal
tumor. When single-copy loss of a chromosome exists in only one
of two distinct tumor cell populations, there is a convolving of
alteration, reducing the magnitude of the event when measured
from the mixed population (Figure S3). Therefore, multiple
putative tumor cell populations differentially affect signal in a
local manner, at distinct regions in the same tumor. Consequently,
we chose an individual-tumor alternative to a global threshold for
alteration, the former being more sensitive to the detection of this
sort of cryptic signal.
Incoherence of copy-number profile. Finally, inaccuracy
in copy-number segmentation is the last extrinsic source of
variation compromising event detection in individual tumors. A
large amount of information is encoded by original probe-level
data on dense arrays such as the Affymetrix 250 K SNP array.
Segmentation is designed to reduce that information content to a
minimal set of discrete gains, losses, and neutral copy number.
The greatest reduction in information is in samples producing few
segments, and least in samples of high segment count (Figure S4).
However, this does not have a coherent relationship to probe-level
noise (Eq. 1, Methods). Consequently, because the features of
probe-level noise are different from those of segmentation, we use
only the latter at all subsequent stages of analysis.
Multi-component scoring model for copy-number
alteration
To adapt to this diversity of variation among individual tumors,
we developed an adjustable multi-component model to detect
aberrations, the first core feature of RAE. We begin by separating
segmented copy-number into four components, each encoding the
status of an alteration type; single-copy gain (A0), amplification
(A1), hemizygous loss (D0), and homozygous deletion (D1). This
separates both the analysis of total gain from loss, but also specific
and intuitive classes of each. This is necessary because each
alteration presents different analytical challenges, not only in
dynamic range, but also in their noise characteristics, which is
often overlooked. Also, by dividing total signal into these four
distinct classes, it is possible the model can extract more
information and produce higher accuracy in individual event calls.
Gain. In the analysis of a set of tumors, there are two
attributes that describe copy-number gain, frequency and
amplitude. At the single-sample level, this equates to a
‘‘detector’’ and an ‘‘integrator’’, the former identifying the
existence of an event and the latter assigning it a magnitude
proportional to its original amplitude. We reasoned that encoding
the detection of an event separately from its amplitude would have
several benefits: (i) a detector operates at the margins of signal and
noise and must be robust to the introduction of wild-type signal, (ii)
because amplitude is unbounded and varies as a function of
stromal contamination, it should be standardized to facilitate
between-tumor comparability, and (iii) in our statistical model that
tests whether an alteration exceeds a random aberration rate,
which is based primarily on recurrence across samples, we want to
boost our power for detecting infrequent but very high-amplitude
events. So, these are separately encoded as single-copy gain (A0)
and amplification (A1).
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PLoS ONE | www.plosone.org 2 September 2008 | Volume 3 | Issue 9 | e3179Figure 1. Overview of the RAE workflow. Input is a set of patients; tumor DNA, (un) matched non-tumor DNA, and an unrelated reference
normal cohort. Tumor and non-tumor samples are quantified, normalized, and subject to quality control. In the assessment phase, individual samples
are segmented and a multi-component model is parameterized for each; this produces a detector for single-copy gain, amplification, hemizygous
loss, and homozygous deletion. Across all tumors, a unified breakpoint profile (UBP) is derived from the ensemble of segmentation breakpoints, and
each region is scored for gain and loss. A background model of random aberrations is constructed with supplemental cleavage and permutation of
genomic regions, and p-values are assigned and corrected for multiple hypothesis testing. In the output phase, RAE determines genomic boundaries
for regions of interest (ROI), controls for germline and population copy-number variation, and reports statistically significant alterations.
doi:10.1371/journal.pone.0003179.g001
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differently, though with a similar conceptual framework. There are
several challenges unique to allelic loss that justifies a modified
approach, and each of these has an important biological corollary.
First, deletion is restricted in its range; only two copies of a locus
can be lost. This is different than amplification. Lacking real
magnitude, DNA is either ‘‘present’’ or ‘‘absent’’, and therefore an
identical scoring scheme would be inappropriate. This complete
absence of signal (or magnitude) corresponds to homozygous
deletion. The second analytical complication is negative skew in
the distribution of segmentation around the diploid peak (Figure
S5). Thus far, this is a feature unique to genomic loss and
complicates the detection of hemizygous loss when its transition
from wild-type signal appears featureless. Nevertheless, accurately
detecting single-copy loss is important. The biological parallel is a
classical tumor suppressor model, one in which somatic mutation
or methylation in one allele is coupled to loss of the other. These
losses are often broad, and may target multiple loci, reducing the
function of more than one gene. However, this falls at the margins
of detectability in such a noisy system. To overcome these
complexities, we also separate deletion into two components.
Unlike the model for gain, both components are ‘‘detectors’’, one
for hemizygous loss (D0), and the other for homozygous deletion
(D1) (parameterization discussed in Methods S1).
Soft discrimination. While there are many options for
detecting these alteration types, a key feature of our approach is
the use of soft discrimination. Providing a robust (and binary) value
for the existence of an event in a noisy system is difficult. This is
exacerbated for single-copy events at the margins of signal and
noise. Consequently, we found that even after segmentation, a
dataset-wide log2 threshold for detecting alteration underperforms
in such a noisy system (data not shown). Alternatively, there is
significant precedent for using soft discriminators in noisy systems,
and we adapt this principle to detect copy-number alteration. For
example, consider alteration of a locus in two tumors, both having
similar amplitudes. The former exceeds a hard threshold by a small
magnitude; the latter does not, but again by only a small
magnitude. It is unlikely that this nominally similar locus results in
altered biology in the former, but the latter is effectively penalized
(Figure 2A). So, to achieve soft discrimination of each alteration
type, we use a sigmoid function with parameters for location (E)
and slope (b) (Figure 2B, Methods). This function maps continuous
log2 ratios, theoretically spanning 6‘, to a constant value between
0 and 61 (depending on the sign of b). By varying the magnitude
of b, we can make the function behave more or less like a sharp
threshold. Additionally, because the parameters (E,b) are
determined from individual tumor data and adapted to each
alteration type, we can vary the function’s sensitivity,
accommodating the very different patterns of noise previously
discussed (Figure 2C, Methods S1). This adaptive
parameterization is also a mechanism by which we can extract
information from even the most challenging tumor profiles. This
flexibility partially eliminates the need for subjective quality
control in the elimination of fundamentally uninformative
samples. For individual tumors having a complex and/or
incoherent pattern of signal (Figure S5), parameterization
produces conservative values of E and b for each alteration type,
suppressing a large fraction of the total signal by design. This is
especially important for the analysis of uncommon tumor types
where source material is at a premium and the elimination of
samples a distinct drawback. Finally, when soft discriminators for
single-copy gain and for mono- and biallelic losses are combined
across all tumors, they are a proxy for the recurrence of each
alteration type. This aggregation across tumors is the subject of the
next section.
Aggregating alterations
A unified breakpoint profile (UBP). We were interested in
identifying the most realistic unit of the genome on which
alterations likely arise and for which our multi-component model
should be assessed statistically. As with benign variants, pathogenic
changes are segmental, altering ,kilobase to whole-chromosome-
Figure 2. Multi-component model of copy-number alteration. (a) In a noisy system, a soft discriminator (red) is juxtaposed to a hard
threshold (black); both of which assign points either continuous or binary values respectively (parentheses) for confidently copy-neutral or amplified
loci (black) and for challenging cases at the margin of signal (green). This indicates the benefit of soft discrimination. (b) The functional form of the
soft discriminator; a sigmoid function with parameters for location (E) and slope (b). (c) Individual-tumor approach to detecting gain and loss; the
multi-component model parameterized for two tumors (red and blue) indicating that tumor-specific features produce different discriminators for
single-copy gain and loss (solid), amplification (dot-dash), and homozygous deletion (dotted). Parameterization selects values for E and b such that
their magnitude (unsigned) moves in the direction indicated (legend).
doi:10.1371/journal.pone.0003179.g002
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dense set of markers (.238,000) when perhaps only 50,20,000
are truly independent observations? Because lesions alter
fragments of DNA, we felt RAE should operate on these.
Therefore, we took advantage of the breakpoints produced by
individual-tumor segmentation. This explicitly correlates
neighboring probes on a segment with similar copy-number and
approximates structural changes in the genome. We unify the
unique breakpoint positions observed in all tumors and these
create a new division of the genome (Figure 3A, Methods). These
newly defined regions are cancer-type specific and the final unit of
analysis. This avoids both an artificial length scale and the
statistical compromises necessary when operating on individual
markers, such as the impact on multiple-hypothesis testing when
measurements are partially dependent (Methods S1).
Combining evidence of alteration from different
tumors. To report a summary of alterations in these regions
for a collection of tumors, we combined the detected alterations
across all patients. The way in which we do this allows us to assess
the significance of an event through comparison to a null
distribution of purely random aberrations. Each component is
first summarized as the average across samples in each region of
the UBP. We then calculate a summary score (Eq. 3) for both total
gain and loss (A9 and D9 respectively) that combines the evidence
of the individual alteration types (Methods). The principal benefit
of this approach is flexibility. A null model (the subject of the next
section) can be created to evaluate: any combination of the
original four components, summary scores for total gain and loss
(default), or by weighting one alteration type relative to another.
As a final aggregation step, we analytically derive uncertainty in
this summary score for each region of the UBP. This is an
important feature of our approach. By propagating the error of
segmentation from all tumors spanning a given locus, we produce
a representation of the uncertainty in our measurement of
alteration at each locus (Methods S1). This uncertainty is an
intrinsic feature of any scoring model, but is currently not used in
existing methodologies.
A background model. We develop a background model for
assessing the significance of tumor-specific alterations, the third
core feature of RAE. The characteristics of a realistic background
aberration model in human cancers are complex and an
unresolved area of research. In a first approximation, we assume
a tumor’s profile is the combination of both driver and passenger
alterations. Furthermore, regions selected by the tumor span genes
whose perturbed function alters the normal cellular phenotype.
We assume these are embedded amid non-specific aneuploidy,
perhaps the product of increasing genomic instability. This fixes
stochastically acquired changes during neoplastic progression, but
which are fundamentally neutral to tumor biology. This suggests a
process spanning the indiscriminate to the decidedly non-random,
Figure 3. Aggregation and permutation. (a) The density of human recombination hotspots (top; median distance between hotspots is ,55 kb)
spans segmentation (red) of probe-level data (dark blue) in a ,5 mb region of 13q14.13-3 in four pleomorphic liposarcomas. The unique tumor-
associated breakpoints (black arrows) define the UBP (regions r1–6; bottom), the smallest of which (r3) spans four genes including the tumor
suppressor RB1 (direction of transcription indicated). (b) On chromosome 1p, the density distribution of predicted recombination hotspots (red) at a
width equal to the median distance between all p-arm hotspots (56 kb), and the distribution of their randomization (blue). The sampling procedure
respects the shape of the original distribution and therefore the sequence features that underlie it. (c) Size distribution of regions derived from
segmentation and subsequently defined by the unified breakpoint profile (UBP; gray), and those hotspot-cleaved regions of the same permuted
during null model generation (as indicated, blue).
doi:10.1371/journal.pone.0003179.g003
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acquisition of copy-number change. This implies tumor-associated
breakpoints identified by segmentation are only a small fraction of
total breakpoints in the genome. So, we hypothesized that a
background model should incorporate components of this benign
genetic background. In the context of copy-number aberrations,
we chose predicted human recombination hotspots.
Hotspots, a local increase in the rate of human recombination,
are a feature of allelic and non-allelic ((N)AHR) homologous
recombination. NAHR, in turn, is one mechanism by which de novo
structural variants are fixed in the genome. A subset of these
variants produces copy-number change, little of which is
pathogenic. In fact, previous studies associate high rates of NAHR
with segmental duplications. These sequences are therefore
susceptible to break and rearrangement (reviewed in [22,23,24]).
Moreover, copy-number variation is tightly coupled to segmental
duplications in the human genome [9,25]. Consequently, we use a
random process involving recombination hotspots as a proxy for
this mechanism. These hotspots are estimated from patterns of
linkage disequilibrium (LD) between extant individuals, reflecting
recombination occurring throughout their ancestral lineage [26].
We supplement tumor breakpoints in a manner consistent with
both this higher-order structure of the human genome and
patterns of genetic diversity.
We randomized the genomic positions of predicted recombi-
nation hotspots (n=32,996, HapMap phase II [27]) with a
rejection-sampling procedure that simulates the preferential
features underlying the distribution of human recombination
(Figure 3B). These randomized positions are used as cleavage sites
for the largest tumor segments prior to permutation (Methods).
Supplemental partitioning of the genome in addition to that
provided by tumor segmentation prior to permutation also has an
operational benefit. It increases the permutation space in a tumor
when segmentation produces a low segment count of which a
fraction are copy-altered, and the balance are large in genomic
size but fundamentally diploid. Without additional division, the
altered segment can be permuted into a finite number of positions,
constraining the model. Fracturing the largest copy-neutral
segments, however, provides a far greater count of positions into
which the region of interest may be permuted.
Having investigated multiple permutation models, we chose a
null distribution derived from genome-wide permutation (Methods
S1). Briefly, (i) segments in each tumor are further subdivided
(cleaved) at the positions of randomized recombination hotspots,
after which (ii) the UBP is derived again on this modified ensemble
of breakpoints (Figure 3C), (iii) the values of the multi-component
model in each region of this UBP (A0,A 1,D 0,D 1) are permuted
together to another position of the UBP in each sample and re-
combined across tumors (see Methods). This is typically repeated
10,000 times producing a null distribution of .10
8 scored regions.
Assessing significance and identifying regions of interest
To assign statistical significance, separately for gain and loss, we
use this null distribution of permuted data to calculate p-values
based on how often the randomly permuted score exceeds the
sample score (Eq. 3). We then correct for multiple hypothesis
testing with the Benjamini-Hochberg false discovery rate proce-
dure [28]. This correction is done over all tests, which correspond
to regions of the UBP. Depending on the segmentation profile of
samples in a disease type, this results in a reduction of between one
and three orders of magnitude in effective tests as compared to
individual markers. The resulting q-value defines the fraction of
tolerated false positives above a given score arising by random
chance in our background model. Regions are then filtered based
on the q-value with a typical cutoff of 0.01 (FDR#1%).
Regions of interest (ROI). We next explore the final core
feature of RAE, determining the boundaries for regions of
significant amplification and deletion. If an alteration contributes
to oncogenesis, then we assume that region of the genome is
selected for its effect on gene content. This event may alter a single
gene or multiple independent events may target a coordinated
program of genes. These lesions may also co-evolve with random
alterations that have little biological impact. Non-random
alterations are statistically significant relative to our null model
and therefore are candidate regions of interest. Nevertheless,
regions of interest are not rigorously defined, but are intuitive and
motivated primarily by two issues. First, the biological researcher is
interested chiefly in manageable and interpretable events, perhaps
involving a single gene. Second, we see visually in the data regions
of focality where peaks of alteration exist but are confounded by
noisy data, including adjacent or neighboring peaks. To capture
both of these, we implement a two-stage approach to determine
ROIs. The first stage identifies regions of significant alteration
(q#0.01). These will be (i) isolated regions of the UBP (singletons)
where focal alteration affects a single locus, or (ii) multiple
physically adjacent regions that are merged and assigned the
largest genomic boundaries of the event. The second stage is
designed to interrogate these broad gains and losses for peaks of
finer-scale and more significant alteration. These are more likely to
contain oncogenes and tumor suppressor genes, meet the first
intuitive criteria of ROIs, but are complicated most by the second.
Consequently, there are two types of imprecision that affect the
determination of regions of focal alteration. Spatial imprecision is
related to the experimental system, where the true position of
alteration is unmeasured due to marker selection, array
composition, and finite resolution. Measurement imprecision
refers to the error propagated from individual events in each
sample and reflects both noise inherent in the experiment and the
variability produced by sample size. The former is fixed and will
improve as array density increases. The latter is something we
incorporate explicitly into the second stage of our algorithm, but is
missing from prior approaches [13,14,18,29]. For a given broad
region that includes loci exceeding a sensitivity threshold, we
detect peaks in the summary score (L2, Eq. 3). If a peak is detected,
it is merged with adjacent loci in this wider region of significance if
their L2 falls within the peak’s interval of error (Figure 4, see
Methods). In this graphical representation from data, the RB1
tumor suppressor, discussed in greater detail below, is detected in a
peak of similarly merged regions that refines the boundaries of an
ROI from those spanning ,3 mb of sequence and 20 genes to
those ,237 kb spanning just two genes.
Using these intrinsic errors in the second-stage algorithm is
important for several reasons. First, selecting only the maximally
significant locus without consideration for adjacent significance in
either the 5 or 39 direction may produce artificially small peak
boundaries. These may subsequently miss a gene proximal to, but
not encompassed by the event (Figure 4). This potentially
erroneous ‘maximum-peak’ identification may be caused by
nothing more than artifact somewhere upstream in normalization,
segmentation, or scoring. Second, and again an issue important to
the analysis of uncommon tumor types, is the question of peak
detection and target identification from copy-number alteration
when the analysis is based on small sample sizes (,20–50). There
is a term in the measurement of error that scales as one over the
square root of the sample size (1=
ﬃﬃﬃ
n
p
). The difference in effect on
error is acute between samples sizes available for rare tumor types
versus those common epithelial tumor types.
Genomic Aberrations in Cancer
PLoS ONE | www.plosone.org 6 September 2008 | Volume 3 | Issue 9 | e3179Figure 4. Regions of interest (ROI). Deletion of RB1 at 13q14.2–q14.3 in pleomorphic liposarcoma demonstrates features of ROI detection in RAE.
(a) Heatmap of copy number in a small region of 13q in 24 pleomorphic liposarcomas (tumors are rows, markers are columns; color scale as
indicated), and (b) From segmentation, the extent of genomic deletion in a subset of tumors with either hemizygous loss (thin) or homozygous
deletion (thick) (c) Inset, the regions of the UBP at this locus (filled circles), and their summary score (D9, left axis). The combination of analytical error
(error bars) and two thresholds (FDR and peak detection, green) determine the sensitivity of ROI detection. The detected peak (identified by red plus)
is merged with physically adjacent regions that fall inside its error interval (red filled circles and error bars) and define the 5 and 39 boundaries of the
ROI (gray). Statistical significance (q-value) corresponding to summary scores such that permutation is unable to resolve a p-value smaller than 1/
(Np+1) (dotted line, right axis) indicates the necessity for resolving ROIs in the space of the summary score D9. Regional and peak boundaries define
the ROI (at bottom; mb) spanning 20 and two genes respectively, the latter including RB1 (direction of transcription indicated). Note, the region
detected as the peak is void of genic content, emphasizing the necessity for incorporating a measure of uncertainty on its score.
doi:10.1371/journal.pone.0003179.g004
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genome. The final phase of analysis is to control for observed
germline and population copy-number variation (CNV). This is a
common step in many studies. The assumption is that altered loci
spanning observed variations in the genome should be removed
given their ambiguity of origin, being either somatic possibly
oncogenic or germline polymorphic. Nevertheless, three concerns
arise. First, there has been little effort to interpret overlapping
events, the biological significance of which is unclear when a
variant’s frequency in the population is low or undetermined.
Second, existing CNVs are more accurately described as copy-
number-variable regions, the exact boundaries of which are mostly
unknown and perhaps over-estimated [30]. The third relates to
specificity issues during CNV detection given the coverage of the
sum of reported CNV. We implement a repository of
approximately 10,000 autosomal variants (Methods). These span
745 mb of sequence and therefore the likelihood of CNV
overlapping cancer-specific loci in a highly aberrant tumor type
are high.
Our approach is conservative and controls for false negatives.
Copy-number variants are analyzed for overlap with the focal
event boundaries produced by RAE. We use the latter because
aberrations tend to be larger in median genomic size than
polymorphic events (data not shown). The percent sequence
coverage is reported, and the event is classified as potentially
polymorphic, but is not excluded at any coverage threshold. These
simple criteria were designed to control for the removal of truly
somatic events, such that a de novo duplication observed in a prior
study would not invalidate a tumor-associated deletion at the same
locus. A similar approach is used to screen cohort-specific germline
variation (see Methods). However, because these appear in
patient-matched non-tumor DNA, and may be interpreted in
many ways, they are removed from primary results, but reported.
Comparison in a large solid-tumor compendium
To assess the performance of RAE, we compared its results with
those of a recently developed method on two large studies totaling
512 solid tumors (Methods S1). These included copy number array
data from 371 lung adenocarcinomas and 141 primary and
secondary gliomas [18,31]. We found RAE produced good
concordance with published focal events identified by the GISTIC
method. In particular, RAE identified 29 of the 31 (94%) reported
focal amplifications and deletions in lung adenocarcinomas, and
19 of 27 (70%) in glioma (Methods S1).
While we did not expect perfect agreement between the results of
the two methods given their dissimilar analytic approaches, we
investigated the differences in some detail. In the lung adenocar-
cinoma dataset, we quantified concordance in two different ways.
To each region of the UBP derived by RAE for the lung dataset, we
mapped published amplifications and deletions. We then compared
amplified, diploid, and deleted regions between the two methods
and found them to be highly concordant (x
2 statistic .10
4, Methods
S1, Table S4). We then assessed the relationship between each
method’s score (L2 in RAE and G-score in GISTIC) for reach
region of the genome. In the regions of statistical significance from
either method (FDR#0.25 in both), we calculated the non-
parametric Kendall tau rank correlation coefficient between
summary scores of amplification and deletion. We found this
reaffirms the high concordance (t=0.86 and 0.77 for amplification
and deletion respectively). We repeated the latter concordance
estimate on the glioma dataset and found very similar results
(t=0.77 and 0.84 for amplification and deletion respectively; see
Methods S1 for details). Additionally, we manually reviewed each
locus reported by the original studies but not statistically significant
by RAE (Methods S1). Overall, many subtle differences impact
detection, and we describe two. First, the method for scaling tumor
segmentation to a common baseline value (usually log2=0) affects
the status of alterations in a small fraction of the most complex
tumors (Figure S9). This is because common summary statistics like
the median bears little relationship to the putative diploid peak in
tumors where the latter is ill defined. The second affect is of greater
impact. In the majority of tumors, the adaptive parameterization of
Ek from individual noise features is more stringent than are
published symmetric thresholds in log2 copy number (Table S5,
Figure S10). This suppresses possible signal that falls between the
value of a symmetric threshold and Ek in a given tumor. This
produces a global reduction in frequency and therefore affects
statistical assessment in kind. For events detected by another
method and not RAE, it remains to be determined if these are truly
realorthemorestringent Ek correctly suppresses theseasfalse signal
in the noisiest of tumors. In summary, we believe the regions of both
agreement and disagreement highlight the value of investigating
genomic data of this type with multiple approaches, leading to
improved analysis methods and an increasingly complete and
accurately derived profile of chromosomal aberrations [The Cancer
Genome Atlas (TCGA) Research Network 2008, submitted].
Application of RAE to Pleomorphic Liposarcoma
We applied RAE to a new dataset for an uncommon and
challenging subtype of adult soft-tissue sarcoma. Soft-tissue
sarcomas (STS) represent ,1% of adult malignancies, yet their
histological diversity, frequent presentation with advanced disease,
andlackof responseto conventional post-surgical treatmentdrives a
total disease-specific mortality of 50% [32]. Of these, liposarcoma is
the most common, accounting for 20% of all adult sarcoma.
Liposarcomas are classified into three biological groups encom-
passing five subtypes, (1) well-differentiated/dedifferentiated, (2)
myxoid/round cell, and (3) pleomorphic, based on morphological
features and cytogenetic aberrations [33,34]. Dedifferentiated and
pleomorphic liposarcomas are characterized by complex karyotypes
and have gross chromosomal aberrations [35,36]. In contrast,
myxoid/round cell liposarcomas have simple karyotypes with
specific reciprocal translocations. We focus here on the most
biologically aggressive subtype, pleomorphic liposarcoma.
Pleomorphic liposarcoma (pLPS) accounts for ,8% of all
liposarcomas, and represents only 1.6% of all soft tissue sarcomas.
Nevertheless,theyarehighlyundifferentiatedtumors,arefrequently
located in the extremities, and have a disease specific survival of
60% at 5 years for patients presenting with localized disease [37].
Based on morphology alone, dedifferentiated and pleomorphic
liposarcomas cansometimes be difficult to discriminate, even for the
experienced soft-tissue pathologist. This distinction is important
since patients with pleomorphic liposarcoma have a 3-fold greater
risk of distant metastasis compared to patients with dedifferentiated
liposarcoma. Previous work by our group identified a gene
expression classifier that discriminates dedifferentiated and pleo-
morphic subtypes, but whose genes mainly reflect a complex
amplification of 12q13-15 in the former [38].
A collection of tumor and non-tumor DNA specimens from 24
patients were selected and analyzed (Methods). A genome-wide
perspective reveals pleomorphic liposarcoma has multiple regions
of significant copy-number amplification and deletion (Figure 5).
Nevertheless, whole-chromosome arm events, a feature charac-
teristic of multiple epithelial tumor types, are only infrequently
seen. RAE identified broad and focal alterations on 18
chromosome arms (Table 1, Tables S2–S3). On a fine-scale,
several genomic deletions contain well-studied tumor suppressors,
confirming prior observations in multiple karyotypically complex
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alteration, a deletion of 13q14.2–q14.3 including the RB1 tumor
suppressor (,60% of tumors). This alteration is a mixture of
hemizygous loss and less frequent homozygous deletion, the latter
in five samples. RB1 germline mutations in individuals with
hereditary or bilateral retinoblastoma are associated with an
increased risk of sarcoma development later in life [40]. Upon
review, however, none of our pleomorphic liposarcoma patients
had a history of retinoblastoma or prior radiation exposure.
After RB1 deletion, the next most common event was loss of
17p13.1 containing TP53. The pattern of p53 deletions includes
both broad and focal hemizygous loss, and less common
homozygous deletion. We also observe both deletion-associated
and copy-neutral LOH at the p53 locus, consistent with previous
reports (Figure S8). Given the potential therapeutic implications of
the presence and type of p53 pathway alterations [41], we
explored alternative lesions in the pathway in samples in which
TP53 is not deleted. MDM2 (12q15) is gained in four such samples.
Furthermore, upstream of MDM2, pLPS tumors seem to lack
frequent alteration of CDKN2A, only two samples having evidence
of deletion, only one of which is biallelic. However, neither RB1
nor TP53 are also deleted in these samples, confirming their
functional redundancy. There are multiple other alterations
targeting genes involved in these two well-studied pathways
mediated by RB1 and p53; G1/S phase transition during cell
cycle progression, affecting CCNE1, RB1, SKP2, and p53, and
DNA repair, including FANCA, RAD1, RAD52, XRCC6, and
MSH4. A thorough discussion of each is outside the scope of this
report.
In addition to these previously documented targets, RAE also
identified frequent deletion of 17q11.2 containing NF1 (neurofi-
bromin 1). A total of nine pleomorphic liposarcomas have genomic
loss at this locus, eight are hemizygous and one is homozygous.
Germline deletions of NF1 are frequently associated (,50%) with
another sarcoma, malignant peripheral nerve sheath tumors
(MPNST), through its association with neurofibromatosis-1 [42].
The COSMIC database also lists mutations in NF1 in multiple
MPNSTs, colorectal carcinoma, and of course in neurofibromas,
but none yet in liposarcoma [43].
RAE also identified a complex amplicon on 5p containing
CTNND2 (d-catenin). Given the propensity of pleomorphic
liposarcomas to metastasize, the amplification of d-catenin is
intriguing. d-catenin functions as an adhesive junction-associated
protein and its over-expression is associated with the down-
regulation of E-cadherin in prostatic neoplasms [44]. Interestingly,
E-cadherin (CDH1) is affected by frequent deletions of 16q22.1 (in
9 pLPS tumors; Table 1). E-cadherin is a metastasis suppressor
gene mediating cell-cell adhesion. Its down-regulation is associated
with an aggressive phenotype in multiple malignancies. Ostensibly,
the amplification of d-catenin may down-regulate E-cadherin in a
deletion-independent manner. However, these are not mutually
exclusive alterations, appearing together in multiple tumors.
Deletion of E-cadherin is monoallelic in pLPS, suggesting the
product of the remaining allele may be down-regulated by d-
Figure 5. Statistically significant genomic alteration in pleomorphic liposarcoma. The false discovery rate (q-value, left axis) and score (A9
and D9, right axis) for amplification and deletion (positive and negative respectively, labeled) on the 22 autosomes in genomic coordinates
(chromosomes indicated at bottom and in plot by alternating colors, centromere in red). The threshold for significance determines the alterations
subject to ROI detection (green). Maximum observed scores of A9 and D9 unattainable by permutation p-value (parentheses, right axis).
doi:10.1371/journal.pone.0003179.g005
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somatic mutation or promoter methylation [45]. Further work is
needed to functionally validate the role of these alterations in
pLPS.
A significant feature of liposarcomas is the deregulation of
adipogenesis. RAE identified multiple alterations involving genes
with known or putative roles in adipocyte differentiation. While
PPARc is the master transcriptional regulator of adipocyte differen-
tiation, wenoted onlysporadic and sub-significant gainsofthe gene in
pLPS. Nevertheless, there are multiple primary and secondary
adipogenesis-related alterations. These include amplification of 19q
spanning both C/EBPa and C/EBPc. This amplification would
contradict previously observed transcriptional down-regulation of C/
EBPa in similar liposarcomas relative to normal fat. Due to the
complexity and temporal features of adipocyte biology, it is either
unlikely that genomic gains in these genes produces a dosage change,
or they are partially regulated in an allele-dosage independent
manner, such as with JUN amplification-mediated repression of C/
EBPb [46]. So we sought alteration in secondary, regulatory genes in
adipogenesis. Indeed, there is an interesting deletion of 12p13.33
spanning several genes of interest. In all, 11 tumors had monoallelic
deletion of this locus. We focus here on WNT5B (wingless-type
MMTV integration site family, member 5B), which is implicated in
the promotion of adipocyte differentiation through its inhibition of
Wnt/b-catenin signaling [47]. In pre-adipocytes, the over-expression
of WNT5B promotes adipogenesis through the reversal of Wnt
signaling inhibition by Wnt3a-mediated nuclear translocation, and
activation of b-catenin, described as an anti-adipogenic signal.
Genomic deletion of WNT5B may imply tumor suppressor function,
its loss relieving Wnt signaling of the competing inhibition, and
allowing the pathway to exertitsnegative regulation of PPARcand C/
EBPa [48].
Table 1. Alterations in the pleomorphic liposarcoma genome.
Locus Region (Peak)* Q-value
{
Number of
genes{ Genetic elements of interest
Spanning known structural variation
(CNV)1#
Gain Loss Unknown
Gain
1p31.2–p31.1 68313202–77461343 1.51E-05 27(1) TNNI3K,MSH4,hsa-mir-186 8.8 (8.7) 11.1 (6.1) 6.9
5p15.33–p15.32 165712–5444231 1.86E-04 28 TERT 53.1 (22.2) 18.9 (5.9) 27.3
5p15.2 10731281–11126282 4.69E-03 2 DAP - 38.1 (3.5) -
5p15.2–p15.1 11413893–15762298
I 1.02E-03 7 CTNND2,FBXL7 3.7 (4.5) 7.7 (6.6) 14.1
5p13.3–p12 32750418–45758751 1.51E-04 64 AMACR,C1QTNF3,RAD1,SKP2,LIFR 8.5 (4.1) 4.1 (1.4) 2.3
7p21.3–p21.1 8732462–20510540 7.78E-04 26 ETV1,TWIST1,TWISTNB,ITGB8 21.1 (1.6) 29.5 (1.6) 14.5
7p15.3–p14.3 23715756–32063427 2.50E-05 51 HOXA9,HOXA11,HOXA13,JAZF1 8.8 (4.3) 6.7 (1.6) 5.5
19p12–q13.11^ 24161928–40254153 ,5.22E-06 43 CCNE1,LRP3,CEBPA 7.3 (1.7) 3.5 (3.2) 11
32690406–34776985 1.51E-05 1 UQCRFS1 4.7 (3) 16.2 (2.2) 27.9
38552698–38678914 ,5.22E-06 2 CEBPG 87.6 (2.5) - 100
19q13.12 40680588–41040430 5.49E-03 21 ETV2,MLL4,PSENEN - 3.7 (1.7) -
Loss
1q41–q42.12 216302655–221524000 4.51E-03 29 MARK1,DISP1,TP53BP2,MIA3 0.6 (1) 0.3 (1) 13.8
10q21.3–q22.1
$ 68571354–70982955 2.65E-05 24 CXXC6,CCAR1 3.8 (5.5) 3.1 (1.6) 7.2
10q22.1–q22.2
$ 72407412–76912067 2.65E-05 46 MYST4 14.8 (3) 1.4 (1) 4
10q24.32–q24.33 103687999–105303029 8.21E-06 33 SUFU,NFKB2 - 1.2 (1) -
10q26.11–q26.3 119097873–135323432 5.35E-05 98 CTBP2,FGFR2 17.8 (4.6) 10 (5.1) 13.9
12p13.33 456768–1673782 1.15E-05 9 RAD52,ERC1,WNT5B,ADIPOR2 39.3 (4) 0.7 (1) 33.2
13q14.2 47917390–48154504 ,5.74E-06 2 RB1 35.9 (1) 35.9 (1) -
16q22.1 67103973–69257715 3.69E-03 32 CTF8,CDH1,CDH3,FUK,NQO1 14.3 (5.2) 31.1 (2.8) 21.3
17p13.1 6791092–7741807 ,5.74E-06 57 TP53
& -- -
17q11.2 24079567–27921023 1.18E-03 49 NF1,SUZ12 5.1 (1) 4.7 (2.3) 8.2
22q13.1–q13.31 39296203–46069760 2.02E-04 84 MKL1,ST13,EP300,XRCC6,PPARA 12.4 (3.4) 11.5 (3) 17
*Genomic boundaries detected as peaks within regions of contiguous alteration are indented.
{False discovery-corrected p-value.
{RefSeq (hg17); in parentheses, human microRNAs.
1Locus of alteration spanning known population CNV (see Methods), percent genomic coverage; in parentheses, mean sample count.
#Unknown: ambiguous direction of copy-number variant.
IBoundary spans multiple observed intragenic breakpoints.
&TP53 is focally deleted (peak, chr17:7501467–7574417), but high in analytical error on low-marker count segments.
$Marginal evidence of germline alteration in only two normal samples.
^Non-genic germline signal in six normal samples spanning only a fraction of the locus, terminating prior to genic content.
Broad and focal alterations stratified by event type. The genetic element of interest is selected from the total genic content of an alteration if it has previously observed
somatic mutations in cancer (COSMIC), known oncogenes or tumor suppressors (CGP), implication in pathways altered in liposarcoma, or novel genes of interest for
further study [43,62,63].
doi:10.1371/journal.pone.0003179.t001
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control of adipocyte differentiation is the monoallelic deletion of
22q13.1–q13.2 including EP300 (EIA binding protein p300). This
well-studied transcriptional co-activator is a putative tumor
suppressor in multiple epithelial tumors and is part of a
t(8;22)(p11;q13) translocation in acute myeloid leukemias (AML)
[49]. EP300 is necessary for the induction of PPARc target genes,
and its decrease suppresses PPARc target gene expression [50].
This produces a concomitant down-regulation of preadipocyte
differentiation. This implies, similar to WNT5B, tumor suppressor
function in pleomorphic liposarcoma, though the status of the
remaining allele is unknown. Considered together, these results
indicate substantial alteration to pathways that exert either pro- or
anti-adipogenic regulation in pleomorphic liposarcoma.
Finally, we wanted to design an approach that was suitable for
exploring different classes of copy-number alteration. This
includes alterations in pleomorphic liposarcomas that were also
altered in a subset of high-quality matched normal DNA and
subsequently classified as germline CNV (Figure 1). These are
usually discarded a priori, as it remains unclear how best to resolve
these as either benign variation, or variants conferring disease
susceptibility. In pLPS, this included a focal amplification of
1p22.2 (from 91.33 to 91.46 mb, q-value=0.021) spanning a
single gene, HFM1, a putative human DNA helicase. Nine tumors
were altered at the HFM1 locus, as were two of their non-tumor
DNA counterparts. Two additional matched normal samples were
altered at the locus, but their respective tumors were not. Also,
there is a dearth of population CNV at this locus. hHFM1 encodes
multiple conserved DNA/RNA helicase sequence motifs, is highly
conserved with the Saccharomyces cerevisiae gene Mer3, a known
helicase, and is preferentially expressed in germline tissues [51].
These results provide a hypothesis regarding a possible role of
HFM1 in susceptibility to soft-tissue sarcoma and extensive tumor
aneuploidy.
A systematic integration of copy number changes with transcript
array data and DNA sequence changes is currently underway in
this and a larger set of sarcomas, which will provide a broader
genetic landscape of adult soft-tissue sarcoma [Barretina J, Taylor
BS et al. 2008, in preparation].
Discussion
The present work details a novel method for mapping and
assessing the significance of chromosomal abnormalities in cancer
based on high-resolution array profiles of tens to many hundreds
of tumor samples. As recurrent changes in a collection of tumors
are more likely to represent candidate functional events than are
those appearing to be randomly acquired, quantitative measures
and statistical assessment are central to the method. For technical
validation, we compared the performance of RAE to the GISTIC
method in a large collection of solid tumors including lung
adenocarcinomas and primary and secondary gliomas. As a
discovery application, we used RAE to determine the spectrum of
copy-number alteration in pleomorphic liposarcoma patients.
Separately, we have used this method to identify significant
alterations in additional glioblastomas, thyroid carcinomas,
localized and metastatic prostate cancers, and additional subtypes
of soft-tissue sarcoma (unpublished work). In comparison with
other methods, the key advantages of our approach are that it: (i)
treats the analysis of genomic gain and loss differently,
distinguishing between four classes of alteration in a manner that
reflects their biological differences, (ii) each of these four scoring
models are sample-specific, adapted to individual tumors to
account for their differences, (iii) we use soft discrimination in lieu
of hard thresholds for improved signal extraction, and (iv) in a
collection of tumors, it generates a random aberration model using
a background of more realistic segmental DNA, rather than
unrealistically independent array markers. The RAE method is
flexible; it is suitable for analyzing data from any array platform or
cancer type varying from genetically simple to chaotic. This
includes the accommodation of new chip types or increased
resolution. Also, RAE is modular. For example, after the
generation of the UBP, alternative algorithms can be substituted
to achieve varying analytical goals. Or, while modifying the initial
phases of the framework, the later components are valid and
applicable for the analysis of copy number changes produced by
next-generation sequencing.
Of course, the distinction between driver events and biological
neutral passenger changes is difficult to achieve definitively. While a
clonal population of tumor cells selects for changes conferring a
growth advantage (driver), it also propagates non-functional
(neutral) alterations. Indeed, recent work in a related domain,
large-scale sequencing of solid tumors, demonstrates the statistical
challenges in attempting to make this distinction
[52,53,54,55,56,57]. For DNA copy number, these challenges
result from the complexity and tumor-to-tumor variability of the
data, even in clinically well-defined tumor types. For realistic
statistical assessment in a collection of tumors, we feel that an
individual-tumor noise model producing sample-specific effective
thresholds is more appropriate than a single global threshold and
that separate treatment of different types of copy number changes
is very useful in practice. We are also confident that random
perturbations using the unified breakpoint profile (UBP) provide a
much more realistic background (null) model than random
perturbations of a much larger number of (linked) individual
probe data points. However, the count of truly independent
regions of change is likely still lower than implied by the UBP
model. Therefore, as background models become more sophisti-
cated in their modeling of random aberrations, one should
explicitly include additional mechanisms potentially mediating
copy number change (prior to any selection). This includes
perhaps a proxy of non-homologous end joining (NHEJ), which is
a prominent feature of rearrangements in tumor cells, as well as
other mechanisms. Finally, no gold standard of experimentally
validated alterations in a large tumor collection exists, which is a
necessary step to elucidate the features of varying methods and the
positive and negative results they generate.
DNA copy number data has clear limitations. Alterations in
most cancers are large, spanning many tens if not hundreds of
genes, many of which are likely not involved in oncogenesis.
Identifying the small number of targets from these events even
across many tumors is difficult. Additionally, oncogenic activation
by mechanisms other than amplification or deletion, like mutation
or epigenetic silencing is also important. Therefore, major
advances in our understanding of cancer genetics will likely come
from integrating copy number data with additional genomic data
types and, of course, functional genetic experiments, both large-
scale and hypothesis driven.
Materials and Methods
Array pre-processing, segmentation, and quality control
Genomic DNA was extracted from tumor and either normal
adjacent fat, muscle, or blood and genotyped with Affymetrix
250 K oligonucleotide arrays (StyI) according to manufacturers’
specifications. Raw data from the 270 HapMap individuals
hybridized to the Affymetrix GeneChip Mapping 500 K array
set were downloaded from NCBI GEO (accession number
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randomly chose a set of 140 individuals as the reference normal
dataset (CEU: 20 Utah residents with northern and western
European ancestry; CHB: 45 Han Chinese in Beijing; JPT: 45
Japanese in Tokyo; YRI: 30 Yoruba in Ibadan, Nigeria; Methods
S1, Table S1, Figure S2). This set was randomly partitioned into
two subsets (HapMap.A: n=40; HapMap.B: n=100). All
Affymetrix data was processed from original CEL files with the
Affymetrix Chromosomal Copy Number Analysis Tool (CNAT
4.0, 1.5.6_v3.1). Genotyping, probe-level signal intensity normal-
ization (quantile), and copy-number quantification of tumor,
matched normal, and HapMap.B samples were generated from
the unpaired sample workflow (CNAT) with HapMap.A samples
serving as the internal control, and with default parameters and a
Gaussian smoothing bandwidth of zero (Methods S1). Copy
number was converted to a tumor-to-normal log2 ratio by
subtracting from the tumor signal at each marker the median
signal intensity of HapMap.B samples. Samples were then
segmented with the Circular Binary Segmentation algorithm
(CBS; a=0.01, permutations=10,000, undo.splits=none) [58].
We normalized segmentation output in the following way. First,
we calculated a measure of sample-specific probe-level noise equal
to the difference in signal between adjacent markers (probes) on
the array: for each sample j, the derivative noise DNj parameter is
DNj~median riz1{ri jj ðÞ j ð1Þ
where ri is the log2 ratio of signal for the i
th marker. We used the
median because of its robustness to non-noise outliers that
correspond to valid segmentation breakpoints. The density
distribution of segmentation (segment means mapped to their
resident probes and therefore scaled by size) was calculated with a
width based on the value of DNj, and mode-centered per sample.
The technical failure criterion was a tumor genotype call rate
(when available, Affymetrix-only) of less than 85%.
The soft discriminator model
Let aij represent normalized log2 copy number at each marker i
in sample j; we derived four sigmoid detectors (S), one for each
alteration state (component) k where k={A 0,A 1,D 0,D 1} and
correspond to single-copy gain, amplification, hemizygous loss,
and homozygous deletion respectively, such that:
Ska ij ðÞ ~
1
e
{bk aij{Ek ðÞ z1
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Similar to the logistic function, Sk(?) maps log2 ratios to values
bounded by 0 and 1 subject to parameters Ek and bk. We derived
four sets of these parameters, one for each alteration state k, which
were adaptively determined per sample (Methods S1). The
truncated sigmoid of A1 (Eq. 2) was designed to integrate aij,
assigning a value that was monotonic to the original magnitude of
the event.
To transition from scoring markers to scoring regions, and for
each region and in each sample, we calculated the weighted
arithmetic mean for each Sk across the m markers in that region.
We then calculated the mean Sk across all samples in each region
of the UBP. These individual Sk scores were also used to compute
summary scores of total gain and loss, for which we used the L2
norm:
A0~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S2
A0zS2
A1
q
and D0~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S2
D0zS2
D1
q
ð3Þ
This scoring approach is flexible. Any of the components (k) can
be statistically assessed independently, combined as above (used in
this paper), or weighted with coefficients (data not shown) such
that one Sk is perceived as substantively more important for the
desired event detection than another.
Unified Breakpoint Profile (UBP)
To generate a common division of the genome for between-
tumor analysis, we combined segmentation breakpoints from all
tumors. For segments of $3 markers, we extracted the unique set of
start positions. To each of these we assigned a terminusposition that
is the marker directly 59 of the next adjacent start site. This simple
procedure covers all segments and samples, is a common division of
each chromosome derived directly from original segmentation
breakpoints,andisnot subjecttoanartificiallengthscale.Thislatter
point avoids unnecessary and likely inaccurate assumptions about
array resolution or alteration size that are study/tumor-type-
specific. We note some variability exists in the position of similar
breakpoints between tumors. While repetitive breakpoints between
tumors were inherited as a single unique position, we frequently see
breakpoints with similar but not identical genomic positions. From
tumor to tumor, these vary by a single marker in either the 59 or 39
direction. This is likely caused by the finite resolution of the
experiment such that the true breakpoint is proximal to the markers
on the array. Operationally, this produces either (i) an isolated
single-marker event during between-tumor aggregation, or (ii) a
contiguousstretch ofsingle-markerevents.Wethereforemergedthe
former to the physically adjacent 39 region, while the latter were
consolidated as an independent region.
Finally, problematic segmentation will result in a sub-standard
UBP. Two problematic sample types exist. Non-tumor cell
contamination tends to cause under-segmentation, producing
large segments of reduced mean amplitude and fewer disease-
associated breakpoints. Conversely, excessive array noise can
produce over- or hyper-segmentation (Methods S1, Figure S6). To
account for both, we derived the distribution of segment counts for
a cohort and outlier samples (with too few or too many segments)
were excluded from UBP generation. From our recent experience
with an internal repository of 1,426 tumors spanning 11 tumor
types of mixed karyotypic and genetic complexity, a median of
,4% of tumor samples in any individual study were excluded by
this step (unpublished work). Nevertheless, after UBP generation,
these samples were added back and assessed because even poorly
segmented samples may bear an underlying disease-specific profile
(Figure S7).
Null model generation
We used human recombination hotspots (n=32,996) predicted
from phase II HapMap data (release 21) [27,59] to further divide
the genome prior to generating the null (background) model.
However, there exists systematic and fine-scale heritable variation
in hotspot use [60]. Therefore, to arrive at a generally valid
background model, we randomized the positions of these hotspots
in a manner sensitive to their physical distribution in the genome.
Let R(h) represent the distribution of hotspots on a non-acrocentric
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between all hotspots on that arm (ranging from 38 to 63 kb across
the 39 arms), with R(h) normalized to range between 0 and 1. We
randomly selected a genomic position xp on the arm and a value of
up from the uniform distribution U[0,1]. If up,R(hp), then xp was
accepted, otherwise, it was rejected and the process was repeated.
This continued until the count of accepted positions, i.e., random
genomic positions according to R(h), equaled the real count of
hotspots on that chromosome arm. This process preserved, on
average, the spatially non-uniform structural features of the
original distribution (Figure 3B) [26,27].
To generate a usable background breakpoint pattern, these
randomized hotspots were mapped to the marker nearest each in
the genome, which was then used as the position of random
cleavage. To prevent excessive fracturing of the original tumor
segmentation profile, we added a breakpoint at the hotspot site
only for segments of size greater than the median size of all
segments by disease type. Furthermore, a breakpoint was added
only when the resulting segments were $2 markers in length and
had a size of no less than one half the original global median
segment size. Each split inherited the copy number assigned to its
parental segment, which maintains the correlation in copy
number. This procedure effectively maintained the mode of the
distribution of event sizes, allowing for a permutation of copy
number values and not positions, without decoupling a possible
relationship between amplitude and size (data not shown)
(Figure 3C). This is desirable as a measure of model simplicity,
as permuting variable-sized fragments of DNA between differently
sized chromosomes is complex. From this cleaved profile of tumor
segmentation, we generated a new unified breakpoint profile and
scored each new region as before. These steps were repeated for
every 1,000 permutations of the null model. Each of these
permutations was a genome-wide randomization in each tumor of
the regenerated UBP and the scores assigned to these regions by
each of the four components.
Regions of Interest (ROI)
As discussed in the text, the first stage of the ROI algorithm
identifies all contiguous regions of statistically significant alteration.
We describe the second stage of the algorithm here. First, in each
of these larger regions spanning more than one region of the UBP,
we detect peaks in only the subset of regions exceeding an order-
of-magnitude greater significance (q#0.001). This prevents over-
sensitivity of peak detection, i.e., regions of marginally higher
significance (0.001,q,0.01) were deemed neither likely to be
differentially selected for by oncogenesis nor to reflect a substantial
increase in either recurrence or magnitude. Second, for eligible
regions (q#0.001), we detected peaks in the summary score (Eq. 3)
and not in their p- or q-values. This is because the number of
random samples one can practically generate with available
computer resources limits the smallest p-value. This would restrict
our ability to identify tumor events with scores greater than the
maximum scoring random aberration of the background model
(assigning a p-value corresponding to 1/(Np+1) to the tumor event,
where Np is the count of random aberrations) (dashed curve in
Figure 4). Because this affects regions of greatest interest, we
determined peaks with a simple detector of local maxima in A9
and D9 as these are monotonic with the p-value and maximally
resolved for any region of the UBP. These peaks, especially in
analyses of uncommon tumor types, are sensitive to the level of
error in the system (see text). Therefore we analytically derive a
unique and symmetric value of error for each region of the UBP
and this determined the sensitivity of peak detection in two ways
(Methods S1). First, the detector identifies zero, one, or more
peaks (identified with red plus in Figure 4) based on a shoulder
sensitivity parameter that we set to two times the median analytical
error of all UBP regions in the larger event (all error bars above
the peak threshold in Figure 4). Second, we assumed that two or
more statistically significant and physically adjacent regions that
are assigned summary scores that lie within the error of the other
likely do not define unique and independent events. Therefore,
regions adjacent to a peak are merged with that locus if their
summary score fell within the error bar of the peak (regions with
red error bars in Figure 4).
Analytical error in the multi-component model
Error was calculated for each of the four components k and for
the final summary scores (A9,D 9). It was computed from the
standard deviations of the original probe-level data in each
segment from each sample spanning a given region of the unified
breakpoint profile (UBP) (details in Methods S1).
Germline variation
Patient-matched normal samples were processed identically to
the tumors. We plotted the distribution of normalized segmenta-
tion and excluded normal samples from analysis if they had; (i)
gross asymmetry, as either negative or positive skew in the diploid
peak producing high proportions of non-neutral copy number, or
(ii) samples with incoherently multimodal distributions of segmen-
tation. We parameterized and calculated A0 and D0 for the
remaining normal samples. We then identified regions of apparent
CNV (polymorphisms in the human population) as loci with A0 or
D0 $0.50 in two or more samples. These were removed from
genome-wide significance plotting, and their genomic coverage
spanning statistically significant tumor regions was calculated and
reported (Tables S2–S3).
Human structural variation
Loci of structural and copy-number variation were obtained
from the Database of Genomic Variants (DGV) at The Center for
Applied Genomics (TCAG; http://projects.tcag.ca/variation)
[61]. Autosomal copy-number variants profiled in any of 35
studies of human genomic variation (version 3) were included in
the screen.
Genome Mapping
All genomic coordinates were standardized to NCBI build 35
(University of California, Santa Cruz (UCSC) May 2004 (hg17)
assembly) of the human genome.
Availability
To support the analysis of copy number data, RAE is freely
available to the research community, located at: http://cbio.
mskcc.org/downloads/rae
Supporting Information
Methods S1 Supplementary methods, results, notes, and
references
Found at: doi:10.1371/journal.pone.0003179.s001 (0.12 MB
DOC)
Table S1 Individuals of the HapMap collection included in the
reference normal
Found at: doi:10.1371/journal.pone.0003179.s002 (0.31 MB
DOC)
Table S2 Additional genomic gain/amplification in pleomor-
phic liposarcoma
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DOC)
Table S3 Additional genomic loss/deletion in pleomorphic
liposarcoma
Found at: doi:10.1371/journal.pone.0003179.s004 (0.13 MB
DOC)
Table S4 Comparison of significant events in the lung and
glioma datasets.
Found at: doi:10.1371/journal.pone.0003179.s005 (0.05 MB
DOC)
Table S5 Values of Ek for lung and glioma datasets
Found at: doi:10.1371/journal.pone.0003179.s006 (0.04 MB
DOC)
Figure S1 Diploid copy number between patient-matched non-
tumor DNA and HapMap reference normal. The distribution of
segment means weighted by their size for a randomly chosen
HapMap individual from the copy-called partition (HapMap.B) of
the reference normal (blue) and three tumor-matched normal
samples (gray). The tight and symmetric diploid peak of the
HapMap individual is juxtaposed to poorly behaved distributions
of patient-matched normal DNA copy-number data.
Found at: doi:10.1371/journal.pone.0003179.s007 (0.33 MB TIF)
Figure S2 Confirming population genetic structure of HapMap
reference normal. Population clustering of n=140, 40, and 100
HapMap individuals from the partitions of the reference normal,
assuming three ancestral populations (k=3; triangle plots).
Clustering is based on the 67 non-redundant biallelic CNVs from
Redon et al. [ref. S3] and repeated on only those 31 genotypes
derived from the Affymetrix early access platform (as indicated).
Found at: doi:10.1371/journal.pone.0003179.s008 (0.85 MB TIF)
Figure S3 Detecting an intermediate phenotype in copy
number. In a single tumor, monosomic chromosome 15 is
adjacent to intermediate signal on chromosome 14 (probe-level
data in gray, segmentation in blue). At right is the density
distribution of autosomal segmentation weighted by event size
(same annotation as in Figure S5). The peak representing the
medial loss signal (green plus) may arise from either multiple
tumor-cell populations in the DNA isolate, or allele-specific copy
number (dark red sigmoid; D0 parameterized with indicated values
of E and b).
Found at: doi:10.1371/journal.pone.0003179.s009 (0.62 MB TIF)
Figure S4 Relationship between probe-level and segmentation
noise. The two very different types of noise associated with array-
based copy number data. We can view the segmentation algorithm
as a de-noising step that attempts to remove noise in probe-level
measurements to accurately estimate the local copy number. Here,
we measure the efficiency of this noise reduction by calculating the
change in entropy from probe-level data to the entropy for
segmentation values (means). To precisely define the entropy, we
first compute the probability density histograms of both the probe-
level and segmentation data using the R density function with a
fixed bandwidth, limits (from 21 to 1 in log2 ratio units), and a
fixed number of bins (2048). The entropy is then defined as
shannon entropy where pi is the probability for each of the 2048
bins. When segmentation works properly, we observe a large
change in entropy [where DS=S(r)2S(m)] from the probe-level
data (r) to the segmentation values (m). However, the phenomenon
of hyper-segmentation (which we have observed in many tumors;
Methods S1, Figure S6) occurs when the segmentation algorithm
generates a large number segments (far larger a number than are
likely to be in the real data). As one would expect there is a simple
relationship between this over-segmentation and the reduction in
the change in entropy. However, these poorly behaved tumors, as
measured by over-segmentation, seem to be uncorrelated with the
low-level noise in their probe-level data as measured by the
derivative noise (DN; see Methods). The derivative noise is
represented by the size of the circles, where the radius in
proportional to the DN. Notice that DN is roughly uniformly
scattered along the DS x-axis.
Found at: doi:10.1371/journal.pone.0003179.s010 (0.72 MB TIF)
Figure S5 Diversity and heterogeneity of tumor profile. At left is
probe-level (gray) and segmentation data (blue) for 11 chromo-
somes (indicated, centromere in red). At right is the density
distribution of segmentation means weighted by their size (22
autosomes). For each, the sigmoid detecting single-copy gain (A0)
and hemizygous loss (D0) are indicated (red and blue respectively,
parameters labeled). The diploid peak is identified at zero in log2
copy-number (gray line) and the half-maximum values of the
diploid peak are identified (dotted gray lines). (a) Tumor with a
symmetric and well-behaved diploid peak as well as smaller peaks
of detectable signal (at left, on chromosomes 8p, 9, 10, 11, and 15).
(b) A hyper-segmented tumor with asymmetry in the diploid peak
exclusively in deletion, challenging the choice of E for single-copy
loss (D0). Nested signal can be detected in the form of whole-
chromosome loss of chr15, an event detected in panel A as well. (c)
A tumor having a highly complex and reduced-quality segmen-
tation profile, gross asymmetry in both gain and loss, an ill-defined
diploid peak, and lacks discernible features for the selection of
parameters for its transformation in either gain or loss.
Found at: doi:10.1371/journal.pone.0003179.s011 (1.69 MB TIF)
Figure S6 Hyper-fragmentation of copy number segmentation.
(a) Normalized probe-level (gray) and segmentation (green) of
chromosome 1 in a single tumor displaying a hyper-fragmentation
pattern. (b) The same probe-level signal as in panel A,
superimposed with a spatially averaged (bandwidth of ,601 kb)
version. Convolved trace indicates a non-disease related period-
icity in signal likely the source of hyper-segmentation (Methods
S1).
Found at: doi:10.1371/journal.pone.0003179.s012 (0.94 MB TIF)
Figure S7 Varying segmentation quality between tumors does
not preclude detection. Here, three chromosomes (14, 15, and 16)
in two tumors, probe-level (orange and light blue) and segmen-
tation data (red and dark blue, respectively). A high-quality
segmentation result (dark blue) identifies monoallelic loss of the q-
arm of chromosome 15. The lower-quality hyper-segmentation
(red) also includes the 15q loss (highlighted). This motivates the
conditional inclusion of both samples during scoring and
assessment, but not the latter during UBP derivation.
Found at: doi:10.1371/journal.pone.0003179.s013 (0.93 MB TIF)
Figure S8 Genomic deletion and observed loss-of-heterozygosity
for the p53 locus. Independent hierarchical clustering of copy
number (segmentation, left) and LOH (paired, right) for 2.2 mb of
17p13.1 (columns are samples, rows are markers) indicates two
patterns of alteration in pleomorphic liposarcomas. Deletion-
associated LOH for p53 in three tumors with either broad or focal
deletion (lines connect corresponding samples; black), and copy-
neutral LOH (green).
Found at: doi:10.1371/journal.pone.0003179.s014 (2.93 MB TIF)
Figure S9 The affect of normalization on segmentation profiles.
Here, the median of original segmentation of each glioma tumor
(x-axis) and the distance (offset) of the mode of the diploid peak
from log2=0 are plotted. While the median is a reasonable
approximation for the diploid feature of most tumors, in a subset
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normalized segmentation are substantially different.
Found at: doi:10.1371/journal.pone.0003179.s015 (0.26 MB TIF)
Figure S10 Difference between symmetric global threshold and
Ek from the individual tumor noise model. Here, the Ek value for
A0 and D0 (single-copy gains and losses respectively) are shown for
all 141 tumors of the glioma dataset. This indicates that in the
majority of tumors, the detector for single-copy events in RAE is
more stringent than was the original log2 global threshold used by
the original study (red dotted lines). This is responsible for the
global reduction in alteration frequencies in the RAE analysis.
Found at: doi:10.1371/journal.pone.0003179.s016 (0.26 MB TIF)
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